Impax Pharmaceuticals (IPXL) to Present RYTARYTM (IPX066) Phase III Data on Monday
Tweet
Share
E-mailGet Alerts IPXL Hot Sheet
Join SI Premium – FREE
Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL) said data from the RYTARYTM Phase III and open-label extension trials will be presented at the 65th Annual Meeting of the American Academy of Neurology in San Diego, California, held from March 16 to March 23. IPX066 is an investigational extended-release capsule formulation of carbidopa-levodopa for the treatment of idiopathic Parkinson’s disease.
The presentation of IPX066 posters is as follows:
Date: March 18, 2013 (all posters)Time: 2:00-6:30, with authors in attendance from 5:30-6:30 PM PT (all posters)Location: San Diego Convention CenterPresentation Title and Number:Long-Term Safety of IPX066 Extended-Release Carbidopa-Levodopa Capsulesin Patients with Motor Fluctuations in Advanced Parkinson’s DiseaseAbstract / Poster Number: 3706/ P01.065Presentation Title and Number:Long-Term Safety of IPX066 Extended-Release Carbidopa-Levodopa Capsulesin Patients with Early Parkinson’s DiseaseAbstract / Poster Number: 3662/ P01.064Presentation Title and Number:Analysis of IPX066 Dosing Data in Advanced Parkinson's Disease (PD) PatientsAbstract / Poster Number: 49/ P01.063
The presentation of IPX066 posters is as follows:
Date: March 18, 2013 (all posters)Time: 2:00-6:30, with authors in attendance from 5:30-6:30 PM PT (all posters)Location: San Diego Convention CenterPresentation Title and Number:Long-Term Safety of IPX066 Extended-Release Carbidopa-Levodopa Capsulesin Patients with Motor Fluctuations in Advanced Parkinson’s DiseaseAbstract / Poster Number: 3706/ P01.065Presentation Title and Number:Long-Term Safety of IPX066 Extended-Release Carbidopa-Levodopa Capsulesin Patients with Early Parkinson’s DiseaseAbstract / Poster Number: 3662/ P01.064Presentation Title and Number:Analysis of IPX066 Dosing Data in Advanced Parkinson's Disease (PD) PatientsAbstract / Poster Number: 49/ P01.063
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- BIGG Digital Assets to rename as Surge Digital, consolidate shares
- enVVeno Medical (NVNO) files $100M mixed shelf
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
